Last reviewed · How we verify

Intravenous Fentanyl guided by SoC

Ciusss de L'Est de l'Île de Montréal · FDA-approved active Small molecule

Intravenous Fentanyl guided by SoC is a Opioid agonist Small molecule drug developed by Ciusss de L'Est de l'Île de Montréal. It is currently FDA-approved for Acute pain management in hospital/clinical settings, Perioperative analgesia and sedation.

Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation.

Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation. Used for Acute pain management in hospital/clinical settings, Perioperative analgesia and sedation.

At a glance

Generic nameIntravenous Fentanyl guided by SoC
SponsorCiusss de L'Est de l'Île de Montréal
Drug classOpioid agonist
TargetMu-opioid receptor (OPRM1)
ModalitySmall molecule
Therapeutic areaPain management, Anesthesia
PhaseFDA-approved

Mechanism of action

Fentanyl activates mu-opioid receptors throughout the brain and spinal cord, inhibiting pain signal transmission and producing potent analgesia. When administered intravenously under standard of care (SoC) guidance, it provides rapid onset pain relief and sedation suitable for acute care settings. The 'SoC' designation indicates this is a standard clinical protocol rather than an investigational approach.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intravenous Fentanyl guided by SoC

What is Intravenous Fentanyl guided by SoC?

Intravenous Fentanyl guided by SoC is a Opioid agonist drug developed by Ciusss de L'Est de l'Île de Montréal, indicated for Acute pain management in hospital/clinical settings, Perioperative analgesia and sedation.

How does Intravenous Fentanyl guided by SoC work?

Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation.

What is Intravenous Fentanyl guided by SoC used for?

Intravenous Fentanyl guided by SoC is indicated for Acute pain management in hospital/clinical settings, Perioperative analgesia and sedation.

Who makes Intravenous Fentanyl guided by SoC?

Intravenous Fentanyl guided by SoC is developed and marketed by Ciusss de L'Est de l'Île de Montréal (see full Ciusss de L'Est de l'Île de Montréal pipeline at /company/ciusss-de-l-est-de-l-le-de-montr-al).

What drug class is Intravenous Fentanyl guided by SoC in?

Intravenous Fentanyl guided by SoC belongs to the Opioid agonist class. See all Opioid agonist drugs at /class/opioid-agonist.

What development phase is Intravenous Fentanyl guided by SoC in?

Intravenous Fentanyl guided by SoC is FDA-approved (marketed).

What are the side effects of Intravenous Fentanyl guided by SoC?

Common side effects of Intravenous Fentanyl guided by SoC include Respiratory depression, Hypotension, Bradycardia, Nausea, Dizziness, Chest wall rigidity.

What does Intravenous Fentanyl guided by SoC target?

Intravenous Fentanyl guided by SoC targets Mu-opioid receptor (OPRM1) and is a Opioid agonist.

Related